Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 49Ovarian Neoplasms 31Triple Negative Breast Neoplasms 27Endometrial Neoplasms 25Lung Neoplasms 24Fallopian Tube Neoplasms 22Neoplasm Metastasis 21Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Neoplasms 14Esophageal Squamous Cell Carcinoma 12Esophageal Neoplasms 12Carcinoma, Ovarian Epithelial 9Stomach Neoplasms 8Head and Neck Neoplasms 8Colorectal Neoplasms 8Carcinoma 7Adenocarcinoma Of Esophagus 7Peritoneal Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Melanoma 5Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Small Cell Lung Carcinoma 3Recurrence 3Pancreatic Neoplasms 3Mouth Neoplasms 3

Interventions

Docetaxel 2Cisplatin 2130-nm albumin-bound paclitaxel 2taxane 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Biosimilar Pharmaceuticals 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaccinia × Paclitaxel × 90 days × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡